Desalting & Buffer Exchange

Global Desalting & Buffer Exchange Market to Reach US$2.3 Billion by 2030

The global market for Desalting & Buffer Exchange estimated at US$1.3 Billion in the year 2023, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 8.5% over the analysis period 2023-2030. Filtration Technique, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$1.1 Billion by the end of the analysis period. Growth in the Chromatography Technique segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$331.7 Million While China is Forecast to Grow at 13.0% CAGR

The Desalting & Buffer Exchange market in the U.S. is estimated at US$331.7 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$595.7 Million by the year 2030 trailing a CAGR of 13.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Desalting & Buffer Exchange Market – Key Trends & Drivers Summarized

What Role Does Desalting & Buffer Exchange Play in Biopharmaceuticals and Research?
Desalting and buffer exchange are essential in biopharmaceutical production, where removing salts and exchanging buffers maintains the stability, purity, and bioactivity of proteins, antibodies, nucleic acids, and other biomolecules. These processes are typically performed in downstream bioprocessing, making them crucial for preparing biological samples for drug formulation, analysis, and therapeutic applications. Through methods such as ultrafiltration, dialysis, and size-exclusion chromatography, biopharmaceutical companies can remove unwanted ions, contaminants, and small molecules while preserving the structure and functionality of the target molecules. As the demand for biotherapeutics rises, including vaccines, gene therapies, and monoclonal antibodies, desalting and buffer exchange technologies have become increasingly vital for meeting regulatory requirements and quality standards.

The shift toward automation and single-use technologies has further transformed desalting and buffer exchange processes, especially in large-scale production environments. Automation enables more precise control over concentration and purification steps, while single-use systems help reduce setup time, minimize contamination risks, and provide greater operational flexibility. Consequently, desalting and buffer exchange are now integrated into most stages of biopharma production workflows, from research and pilot stages to commercial-scale manufacturing. The growing emphasis on biopharmaceutical innovation and the industry’s shift to single-use systems indicate that these processes are foundational to advancing high-quality biotherapeutic products efficiently and consistently.

How Are Technological Advancements Shaping This Market?
Recent technological advancements have revolutionized the desalting and buffer exchange market, leading to the development of high-throughput, automation-compatible solutions that enable rapid and consistent sample processing. Innovations like microfluidic platforms, enhanced membrane chemistry, and new resins have significantly improved the efficiency and scalability of desalting and buffer exchange. These technologies enable laboratories and manufacturing facilities to scale operations effectively while reducing contamination risks and waste. As a result, labs and biopharma companies can achieve higher throughput with enhanced accuracy, making it easier to meet the increasing demand for biopharmaceuticals and diagnostics.

Single-use systems have also become a prominent trend, providing flexibility, faster changeovers, and reduced cross-contamination risks in bioprocessing. The integration of IoT and real-time monitoring technology has enhanced control over concentration and buffer composition, streamlining complex workflows and increasing precision in various downstream processes. High-capacity systems are now common, allowing for continuous and automated sample handling, which is essential for large-scale production of biomolecules. With these advancements, desalting and buffer exchange technologies continue to evolve, meeting the biopharma industry’s growing needs for efficiency, scalability, and adherence to rigorous regulatory standards.

Why Are Desalting & Buffer Exchange Applications Expanding Across Industries?
Desalting and buffer exchange processes have extended beyond biopharmaceutical applications and are now widely used in other sectors such as environmental testing, food and beverage, and cosmetics. In environmental testing labs, desalting plays a crucial role in preparing water and soil samples by removing salts and other ions that could interfere with testing accuracy. Similarly, the food and beverage industry utilizes buffer exchange to stabilize enzymes and manage pH levels in product formulations, ensuring consistent quality and safety standards. The cosmetics industry is another significant market, as desalting and buffer exchange support pH adjustment and purification in skincare and beauty products, enhancing product stability and efficacy.

The expansion of desalting and buffer exchange applications across these industries highlights the versatility and effectiveness of these processes for meeting quality and compliance standards. As environmental and safety regulations become stricter, more industries are adopting desalting and buffer exchange to maintain product consistency and comply with regulatory guidelines. This cross-industry adoption demonstrates the broad applicability and growing importance of desalting and buffer exchange processes. With industries such as food safety and cosmetics prioritizing quality control, the use of these processes is likely to grow, fueling further innovation and market demand across various sectors.

Growth in the Desalting & Buffer Exchange Market Is Driven by Several Factors
Growth in the desalting and buffer exchange market is driven by several factors, including rising demand for high-purity biomolecules in the biopharmaceutical and life sciences sectors. The ongoing advancements in high-throughput and automated solutions have enabled scalability and precision in desalting and buffer exchange processes, which is critical for meeting the increasing demand for biologics, vaccines, and personalized therapeutics. The growing preference for single-use technologies is also a significant factor, as these solutions help reduce contamination risks and increase operational flexibility in production environments, particularly in biopharmaceutical manufacturing facilities.

Additionally, the expansion of desalting and buffer exchange applications in non-biopharma sectors such as food and beverage, environmental testing, and cosmetics has broadened the market’s scope, driven by each industry’s focus on quality assurance and compliance. Consumer awareness surrounding product safety and sustainability has further bolstered demand for efficient desalting and buffer exchange technologies, as companies seek eco-friendly and waste-minimizing solutions. Increased regulatory support and investment in R&D, particularly in areas of biotherapeutic production and high-purity standards, also contribute to the market’s growth. As these trends continue, desalting and buffer exchange technologies are likely to become even more integral to the quality and safety standards that modern industries require.

Select Competitors (Total 33 Featured) -

• Agilent Technologies
• Avantor
• Bio-Rad Laboratories
• Bio-Works Technologies Ab
• Danaher Corporation
• GE Healthcare
• Merck KGaA
• Norgen Biotek Corp.
• Phynexus, Inc
• Repligen Corporation
• Sartorius AG
• Thermo Fisher Scientific

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.